Liprolog (Insulin Lispro)

Liprolog, a rapid‑acting insulin, is employed in the management of several diabetic conditions and related emergencies.

• Type 1 diabetes mellitus: provides prompt post‑prandial glucose control.
• Type 2 diabetes mellitus: assists in achieving target glycaemic levels when oral agents are insufficient.
• Diabetic ketoacidosis: supplies immediate insulin activity to reduce ketone production.
• Hyperglycemia: rapidly lowers elevated blood glucose during acute spikes.

• Insulin Lispro binds to insulin receptors on cell membranes, activating intrinsic tyrosine kinase activity. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production, resulting in a rapid decrease in circulating blood glucose levels.

Insulin Lispro may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypoglycaemia: low blood sugar episodes, especially if meals are missed.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase due to improved glucose utilization.
• Lipodystrophy: localized changes in subcutaneous fat.
• Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance.
• Allergic reactions: urticaria, angio‑edema, or anaphylaxis.
• Hypokalemia: low potassium levels, particularly with high insulin doses.
• Acute insulin resistance: unexpected poor glucose response.
• Serum insulin antibodies: may alter drug efficacy.

When prescribing Liprolog, clinicians should consider several safety measures.

• Dose adjustment: tailor insulin dose based on frequent blood glucose monitoring and individual response.
• Renal impairment: monitor closely as reduced clearance may increase hypoglycaemia risk.
• Pregnancy: use only if benefits outweigh potential risks; data are limited.
• Alcohol consumption: may potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.
• Hypoglycaemia unawareness: educate patients on recognizing subtle symptoms.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Insulin Lispro can interact with various medications, affecting glucose control.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms, delaying recognition.
• Monoamine oxidase inhibitors (MAOIs): can increase the risk of severe hypoglycaemia.
• Concurrent rapid‑acting insulins: additive glucose‑lowering effect may cause profound hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or other oral hypoglycaemics: may enhance insulin’s effect, requiring dose adjustments.
• Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy.
• ACE inhibitors: may potentiate insulin’s glucose‑lowering action, necessitating monitoring.